Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
Marco Rubio Visits India to Rebuild U.S.-India Ties Amid Trade and Geopolitical Tensions 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Asian Stocks Rally as Japan’s Nikkei Hits Record High on AI and Chipmaker Surge 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Google Expands AI Partnership With Singapore Government 
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
Oil Prices Drop Below $100 as U.S.-Iran Talks Ease Strait of Hormuz Fears 
Dollar Weakens as Iran Peace Deal Hopes Boost Global Market Sentiment 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
Japan Plans $19 Billion Extra Budget as Bond Market Faces Pressure 
JPMorgan Sees Large-Cap Biotech Stocks Entering New Growth Phase in 2026 
Wall Street Faces Inflation Pressure as Strong Earnings Season Nears End 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Cuba needs a long-term solution to its energy crisis 
Gold Prices Surge as U.S.-Iran Peace Hopes Weigh on Oil Markets 
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
